Email this article 
Efficiency and safety of OctreotidLong FS therapy in acromegaly patients
- Authors: Dreval’ AV, Trigolosova IV, Vinogradova AV, Tishenina RS
- Issue: Vol 7, No 1 (2013)
- Pages: 49-53
- Section: Articles
- URL: https://surg-endojournals.ru/serg/article/view/6371
- DOI: https://doi.org/10.14341/serg2013149-53
- Cite item
Abstract
Aim of this study was to investigate efficiency and safety of OctreotidLong FS in patients with acromegaly. Materials and methods. 41 patients with acromegaly (8 – de novo and 33 patients after different somato statin analogs treatment) was treated OctreotidLong FS one injection in 28 days. Growth hormone (GH), Insulin like Growth Factor 1 (IFG1), fasting glucose (FG) and HbA1c were assess after 3, 6 and 12 month of therapy. Results. We found out the decreasing of GH and IGF1 from 12,8 (8,0–82,7) mU/ml to 3,8 (1,6–13,8) mU/ml ( p < 0,05) and %IGF1 increasing (% IGF1) from 231 (150–286)% to 9,5 (−26–111)% ( p < 0,05) in 8 de novo acromegalic patients. We also revealed that IGF1 didn’t change and GH decreased after 3 month (33 patients), 6 month (22 patients) and 12 month (8 patients) of OctreotidLong FS treatment. We didn’t observed negative effect of OctreotidLong FS treatment to carbohydrate metabolism in patients with acromegaly. Conclusion. The therapy of OctreotidLong FS leads to induce successful control of GH and IGFI in 50% de novo patients and didn’t change the number of patients with control of acromegaly after another somato statin analogs treatment. Carbohydrate metabolism also didn’t change after OctreotidLong FS treatment.
About the authors
A V Dreval’
doktor med. nauk, professor, MONIKI im. M.F. Vladimirskogo.
I V Trigolosova
Email: trigolosova_ira@mail.ru
kand. med. nauk, starshiy nauchnyy sotrudnik, MONIKI im. M.F. Vladimirskogo
A V Vinogradova
vrach, MONIKI im. M.F. Vladimirskogo
R S Tishenina
doktor med. nauk, professor, MONIKI im. M.F. Vladimirskogo.
References
- Древаль А.В., Триголосова И.В., Виноградова А.В., Иловайская И.А. Распространенность сахарного диабета среди больных акромегалией. Проблемы эндокринологии. 2012;3: 9–11.
- Виноградова А.В., Перфильев А.В., Триголосова И.В., Иловайская И.А. Эффективность лечения акромегалии Сандостатином ЛАР в дозах 10–40 мг. Фарматека. 2011;11: 75–79.
- Древаль А.В., Камынина Т.С., Нечаева О.А., Покрамович Ю.Г. Московский областной регистр акромегалии. Проблемы эндокринологии. 2008;(4): 27–31.
- Древаль А.В., Виноградова А.В., Триголосова И.В. и др. Распространенность сахарного диабета среди больных акромегалией. Проблемы эндокринологии. 2012; (3): 9–11.
- Dreval A., Trigolosova I., Vinogradova А., Ilovayskaya I. Prevalence of diabetes mellitus among acromegaly patients. Abstracts of the 15th Congress of the European Neuro endocrine Association, Wien, 22–25 September 2012. P. 40.
- Dreval A.V., Agaltsov M.V., Trigolosova I.V. Influence long acting somatostatin analogue on sleep apnea in acromegaly patients (case report) 14th Congress of the European Neuroendocrine Association, Liege, Belgium, 22–25 September 2010.
- Dreval A., Trigolosova I., Vinogradova A., Ilovayskaya I. Features of glucose metabolism in acromegalic patients in active stage ENDO 2011, Boston, USA, June 4–7, 2011. Endocr. Rev. 2011; 32: 3–272.
- Colao A., Auriemma R.S., Galdiero M.et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulinlike growth fac torI levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 2009; 94: 3746–3756.
- Attanasio R., Baldelli R., Pivonello R.et al.Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J. Clin. Endocrinol. Metab. 2003;88: 5258–5265.
- Ayuk J., Stewart S.E., Stewart P.M., Sheppard M.C. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin. Endocrinol. (Oxf.). 2004; 60: 375–381.
- Carlsen S.M., LundJohansen M., Schreiner T. et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 2008; 93: 2984–2990.
- Melmed S., Colao A., Barkan A. et al. Guidelines for Acromegaly Management: An Update. J. Clin. Endocrinol. Metab. 2009; 94 (5): 1509–1517.
- Definition, diagnosis and classification of Diabetes Mellitus and its complications. Geneva, W.H.O. 1999.
Statistics
Views
Abstract - 1109
PDF (Russian) - 459
Cited-By
